Department of Psychiatry, Faculty of Medicine, University of Leicester, Leicester LE2 7LX, UK.
J Psychopharmacol. 1994 Jan;8(3):185-6. doi: 10.1177/026988119400800308.
Effective treatment with pimozide of a male patient with secondary de Clérambault's syndrome (DCS) and schizophrenia is reported. There was no evidence of relapse at 24-month follow-up. Pimozide is suggested to be the drug of choice in DCS and may be in other disorders in which symptoms of erotomania are prominent. The unique anti-erotomanic activity of pimozide may be due to its calcium channel antagonist activity, a property which is not shared by the other antipsychotic drugs.
报告了一例使用匹莫齐特治疗继发于克莱恩蒙氏综合征（DCS）的精神分裂症男性患者的有效治疗案例。在 24 个月的随访中，没有复发的迹象。匹莫齐特被建议作为 DCS 的首选药物，也可能适用于其他以钟情妄想症状突出的疾病。匹莫齐特独特的抗钟情妄想活性可能与其钙通道拮抗剂活性有关，而其他抗精神病药物则不具有这种特性。
